News | March 21, 2024
Bristol Myers Squibb completes acquisition of Karuna Therapeutics
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
A five-day inspection was concluded successfully with no critical and no major observations raised
Additional capacity broadens Grace’s fine chemical capabilities for API production
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Subscribe To Our Newsletter & Stay Updated
